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Overexpression of the ErbB2 receptor tyrosine kinase is associated with most aggressive tumors in
breast cancer patients and is thus one of the main investigated therapeutic targets. Human ErbB2 C-
terminal domain is an unstructured anchor that recruits speciﬁc adaptors for signaling cascades
resulting in cell growth, differentiation andmigration. Herein, we report the presence of a SH3 bind-
ing motif in the proline rich unfolded ErbB2 C-terminal region. NMR analysis of this motif supports a
PPII helix conformation and the binding to Fyn-SH3 domain. The interaction of a kinase of the Src
family with ErbB2 C-terminal domain could contribute to synergistic intracellular signaling and
enhanced oncogenesis.
Structured summary of protein interactions:
ErbB2 and Fyn-SH3 bind by nuclear magnetic resonance (View interaction)
Fyn-SH3 binds to ErbB2 by surface plasmon resonance (View interaction)
 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction ﬁrst event instructing the cell to proliferate, differentiate, surviveOverexpression of the ErbB2 receptor tyrosine kinase is associ-
ated with the most aggressive tumors in breast cancer [1], inducing
a constitutive ligand-independent activation of intracellular signal-
ing. Experimental studies have demonstrated that ErbB2 receptor
tyrosine kinase confers many properties speciﬁc of a cancerous
cell, such as the uncontrolled proliferation, the resistance to apop-
tosis and the increase in motility. ErbB2 is composed of four
domains: a globular extracellular domain (sequence: 23–646;
structure, PDB code: 1S78), a helical membrane-spanning domain
(sequence: 650–684; structure, PDB code: 1IIJ), a tyrosine-kinase
intracellular domain (sequence: 696–987; structure, PDB code:
3POZ) and an unfolded C-terminal domain, CtErbB2 (sequence:
988–1255). ErbB2 C-terminal domain contains ﬁve speciﬁc phos-
phorylated tyrosine residues which serve as binding sites for PTB
and SH2 domains found in signaling molecules or adaptors among
which Shc, Grb2 or Grb7 [2]. Recruitment of these adaptors is theor migrate. While ErbB2 signaling has been extensively studied,
the structure, the dynamics and the molecular mechanisms of
the unstructured C-terminal domain are not elucidated.
CtErbB2, predicted as an intrinsically disordered domain, is the
hub of a protein–protein interaction network associated with the
ErbB2 receptor and thus plays a crucial role in signaling processes.
Compared to structured proteins, intrinsically disordered proteins
are enriched in P, Q, M, K, R, S and E residues which are associated
with a lack of tertiary structure resulting in a highly ﬂexible main
chain. They are usually described as an ensemble of interconvert-
ing heterogeneous conformations which allow them to interact
with various targets [3]. Linear motifs are short segments forming
structured binding site within a disordered protein [4]. In these
motifs, a great number of proline residues are found either in the
conserved identities or in the ﬂanking regions. The side chain
atoms of proline form a pyrrolidine ring with the backbone atoms
facilitating sequence-speciﬁc recognition in the absence of high
afﬁnity interaction [5]. Such speciﬁc and weak interactions are
essential for cell signaling and communication that require fast
reversible interactions. Polyproline stretches can adopt two unique
helical conformations. Polyproline type I, PPI, is a right-handed
helix consisting of cis-prolines. PPII helix is a left-handed helix
Fig. 1. (A) 15N-HSQC spectra of Fyn SH3 domain at 0.1 mM concentration,
performed in the absence (in black) and in the presence of R1P2Q3P4P5S6P7R8E9
peptide at 0.280 mM concentration (in red), (B) 15N-HSQC spectra of Fyn SH3
domain at 0.1 mM concentration, performed in the absence (in black) and in the
presence of A1P2Q3A4P5S6A7R8E9 peptide at 0.280 mM concentration (in red), (C)
15N-HSQC spectra of Fyn SH3 domain, at 0.1 mM concentration, performed in the
absence (in black) and in the presence of R1A2Q3P4A5S6P7A8E9 peptide at 0.280 mM
concentration (in red).
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date other amino acids such as glutamine, serine and arginine. PPII
helix is an extended structure accommodating three residues per
turn [6]. These linear motifs are largely found in the eukaryotic
proteome and have a great biological importance [7].
CtErbB2 contains 16% of proline residues and the role of the
proline-rich motifs has not yet been investigated. We have per-
formed a bioinformatics analysis of the human CtErbB2 and found
a SH3 binding motif (R1146PQPPSP1152). Using NMR, we have inves-
tigated this linear motif of the CtErbB2 domain and give evidence
that it represents a new binding site for Src family kinases (SFKs).
2. Experimental procedures
2.1. Bioinformatics analysis
Human CtErbB2 sequence was analyzed using Eukaryotic Linear
Motif resource (http://elm.eu.org). A Lig_SH3_1 motif was found in
the sequence from 1146 to 1152 and will be called here-after
[RPQPPSP]-site.
2.2. Protein production and peptide synthesis
A human ErbB2 derived peptide of [RPQPPSP]-site (sequence R1-
P2Q3P4P5S6P7R8E9) and two mutant peptides (sequence A1P2Q3A4-
P5S6A7R8E9 and sequence R1A2Q3P4A5S6P7A8E9, respectively) were
synthesized by Schaffer Company. A 13C-Pro labeled peptide of
[RPQPPSP]-site (sequence R1P2Q3P4P5S6P7R8E9) was synthesized
using U-13C, 15N LproN FMOC provided by CortecNet company.
For Grb2-SH3N domain a plasmid construct was produced
using the pETite N-His SUMO vector (Lucigen Corporation, Middle-
ton, Wisconsin, United states), an enzyme free PCR directional
cloning system. This vector system has an N-terminal His-tag fol-
lowed by a SUMO fusion tag with a SUMO protease site, resulting
in a protein with an additional 107 residues added to the synthetic
gene of Grb2-SH3N domain (MHHHHHHGSLQDSEVNQEAKPEVK-
PEVKPETHINLKVSDGSSEIFFKIKKTTPLRRL MEAFAKRQGKEMDSLT
FYDGIEIQADQTPEDLDMEDNDIIEAHREQIGG). The plasmid pETite–
N-His-SUMO-Grb2-SH3_1 was transformed into HI-Control BL21
(DE3) chemically competent cells for protein expression (Lucigen).
Transformed cells were grown in 4L of M9 minimal medium con-
taining 15NH4Cl (1 g/L) as the only source of nitrogen, and the
expression was induced with 500 mM IPTG (isopropyl b-D-1-thio-
galactopyranoside) at an optical density of 0.6 at 30 C for 16 h
to a ﬁnal optical density of 1.8. Protein was puriﬁed using a Hitrap
Ni IMAC FS 1 mL column (GE Healthcare) with a gradient of imid-
azole. The SH3 domain after cleavage with the SUMO protease was
puriﬁed using the same column. Cleaved GrbB2 SH3 domain was
buffer exchanged to 25 mM phosphate buffer, 150 mM NaCl pH 7
using a HiPrep™ 26/10 Desalting column (GE Healthcare). Finally,
gel ﬁltration was performed using a Superdex 75 10/300 GL (GE
Healthcare) in 25 mM NaPi, 150 mM NaCl pH 7, 25% glycerol.
Fyn-SH3 domain was produced in Escherichia coli BL21 (DE3),
according to [8]. 15N-Fyn-SH3 was obtained using 1 L of M9 mini-
mal medium containing 15NH4Cl (1 g/L) as the only source of nitro-
gen and 15N/13C-Fyn-SH3 was obtained using 2 L of M9 minimal
medium containing 15NH4Cl (1 g/L) as the only source of nitrogen
and 13C-glucose (2 g/L) as the only source of carbon. Protein puri-
ﬁcation was achieved using Ni–NTA afﬁnity chromatography (Qia-
gen) and imidazole gradient.
2.3. Surface plasmon resonance experiments
The dissociation constant value was obtained from titration
experiments performed on Biacore 3000 equipment. Fyn SH3
domain was covalently immobilized on a carboxymethyl-dextran-coated sensor chip by amine coupling. R1P2Q3P4P5S6P7R8E9
peptide was injected at 23.4; 46.8; 93.7; 187.5; 375; 750; 1500;
3000; 6000 and 12000 lM concentration. The dilution series sens-
ograms were evaluated using the BIAevaluation software.
2.4. NMR spectroscopy experiments
All the experiments were recorded at 303 K on a Bruker Avance
III 600 MHz spectrometer equipped with a TCI cryoprobe. For
ErbB2 peptide assignment, natural abundance 13C-HSQC was
obtained on the unlabeled R1P2Q3P4P5S6P7R8E9 peptide, and 13C-
HSQC was carried out on 13C-labeled R1P2Q3P4P5S6P7R8E9 peptide.
TOCSY (80 ms) and NOESY (300 ms) experiments were recorded
on a 3 mM unlabeled R1P2Q3P4P5S6P7R8E9 peptide. All the samples
were in 50 mM KPO4, pH 7.0 and 150 mM NaCl and 90% H2O, 10%
D2O. Structure calculations of the R1P2Q3P4P5S6P7R8E9 peptide
were carried out with CYANA using interproton distances and
backbone dihedral restraints. The accuracy of the NMR models
could be assessed based on the criteria for successful structure cal-
culation using the program CYANA. Each of the 25 lowest energy
structures chosen for the ﬁnal structure ensemble were subjected
to restrained molecular dynamics using Amber 10.
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a 15N–13C-labeled Fyn SH3 sample at 1 mM in 50 mM KPO4, pH 7.0;
150 mM NaCl and 90% H2O, 10% D2O, and HNCA, HNCOCA,
CBCANH, CBCACONH, HNCO and HNCACO heteronuclear
experiments.
Chemical shift mapping of [RPQPPSP]-site on Fyn-SH3 was
obtained from 15N-HSQC recorded on 15N-labeled Fyn-SH3 sample
at 0.1 mM in 50 mM phosphate buffer, pH 7.0 and 150 mM NaCl
and 90% H2O, 10% D2O, in the presence of 0; 0.05; 0.1; 0.2 and
0.4 mM ErbB2 peptide. These experiments were recorded at
303 K on a Bruker Avance III 500 MHz spectrometer equipped with
a QXI probe.
3. Results and discussion
3.1. Identiﬁcation of a class I SH3 binding motif in ErbB2 C-terminal
domain
Human CtErbB2 contains 46 proline residues over 275 amino
acids. The importance of these proline residues in protein–protein
interactions and/or domain ﬂexibility is one of our main focal
points in CtErbB2 structural studies. Human CtErbB2 sequencePept
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Fig. 2. (A) NMR titration of FynSH3 domain/R1P2Q3P4P5S6P7R8E9 peptide complex forma
absence of peptide, blue is the same sample with 80 lM peptide, red with 150 lM pepti
peptide. The plot of 96R chemical shift variations in the presence of R1P2Q3P4P5S6P7R8E9
R1P2Q3P4P5S6P7R8E9 peptide complex formation.(988–1255) was analyzed using the Eukaryotic Linear Motif
(EML) resource to identify functional sites associated to the ErbB2
diseasome. A [RPQPPSP]-site motif was identiﬁed at position
(1146–1152) as a class I SH3 domain binding site (RxxPxxP). In
order to characterize this polyproline motif, we have synthesized
a peptide corresponding to the ErbB2 sequence (R1P2Q3P4P5S6P7R8-
E9). Given that this sequence is located close to one of the phospho-
tyrosine, pY1139, a ligand of the Grb2 and Grb7-SH2 domains, we
decided ﬁrst to verify if the [RPQPPSP]-site could bind one of the
SH3 domains of Grb2 (Grb2-SH3N, for the N-terminal SH3 domain
of Grb2). On the basis of 15N-HSQC of the Grb2-SH3N domain, we
did not observe any chemical shift variation of Grb2-SH3 amides in
the presence of the R1P2Q3P4P5S6P7R8E9 peptide, suggesting that
there is no interaction between the two molecules (data not
shown). Subsequently, on the basis of the predicted data obtained
from the ELM resource, we performed an NMR titration of Fyn-
SH3/R1P2Q3P4P5S6P7R8E9 peptide interactions. 15N-HSQC of Fyn-
SH3 domain recorded in the presence of the ErbB2 peptide
revealed that this peptide induced chemical shifts on some NH cor-
relation peaks of Fyn-SH3 (Fig. 1A). The fast exchange observed
between the free and bound forms were in agreement with a
KD of 0.935 mM as determined by NMR and of 0.909 mM aside  [μM]
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tion. Black is FynSH3 domain HSQC spectrum, at 0.1 mM concentration and in the
de, green with 210 lM peptide, pink with 280 lM peptide and orange with 330 lM
peptide is shown, Dd ¼ ðDdH2 þ ðDdN2 =25Þ1=2Þ [26], (B) SPR data for FynSH3 domain/
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These values are in the range of the weak interactions already
reported for others SH3/ligand complexes [9].
3.2. Structural analysis of ErbB2 polyproline motif
The high content in proline residues in the R1146PQPPSPRE1152
sequence suggested a possible left-handed polyproline type II
(PPII) helix organization of the peptide. In order to conﬁrm that
this peptide has an extended structure consistent with a PPII helix,
we have performed a series of NMR experiments. Our ﬁrst observa-
tions from the 13C-HSQC spectra, shows the 13Cc of proline residues
around 27 ppm and the 13Cb around 32 ppm (Fig. 3A). These values
are in agreement with a trans-conformation for all proline residues
of the peptide, considering that for a cis-conformation these values
are 24.4 ppm for the 13Cc and 33.8 ppm for the 13Cb [10]. Moreover,
on the basis of the sequential assignment of the TOCSY and NOESY
homonuclear spectra of the R1P2Q3P4P5S6P7R8E9 peptide, we could
observe Hai1/Hdi nOes between residues R1 and P2; Q3 and P4 and
S6 and P7 (data not shown). These sequential nOes strongly validate
the trans-conformation of proline residues.
Then, from NMR experiments we could observe that the peptide
contained a single conformation and with the assumption that the
PPII conformation allowed a rigid structure to the peptide, we used
a general relationship between the size of spin–spin coupling con-
stant 3J and the intervening torsion angle h. The dependence of
3JHNa on the torsion angle u in polypeptides was obtained from
the equation 3JHNa ¼ 6:4 cos2 h 1:4 cos hþ 1:9 [11]. From 1D-
proton experiments, we could measure the 3JHNa coupling13
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Fig. 3. (A) Natural abundance 1H–13C HSQC of unlabeled R1P2Q3P4P5S6P7R8E9
peptide at 2 mM concentration, (B) HaHN correlations in 2D homonuclear NOESY of
R1P2Q3P4P5S6P7R8E9 peptide at 2 mM concentration.constants for Q3 (6.5 Hz), S6 (6.4 Hz), R8 (6.9 Hz) and E9 (7.5 Hz).
The plot of 3JHNa versus the torsion angle h provided values around
78 for Q3 and S6 suggesting their implication in an elongated
structure that may be a PPII helix. Nonetheless, these spin–spin
couplings are valuable data in complementation of NOE distances.
The analysis of the sequential nOes gave evidence of strong Hai/
HNi+1 correlation for P2/Q3, P5/S6, P7/R8 and R8/E9 (Fig. 3B) in perfect
agreement with a PPII conformation. Finally, we calculated the
conformation of the peptide using CYANA software. A PPII helix
was clearly obtained from our NMR restraints (Fig. 4A).
The structure of R1P2Q3P4P5S6P7R8E9 peptide contains three res-
idues per turn and residues R1, P4 and P7 lie on the same face of the
helix, each containing side chains with roughly the same orienta-
tions than the peptides 91–104 of the p85 subunit of PI3-Kinase
within the complex with Fyn-SH3 (Fig. 4B). We investigated the
binding of a mutant of the R1P2Q3P4P5S6P7R8E9 peptide where R1,
P4 and P7 were substituted by alanine residues (A1P2Q3A4P5S6A7R8-
E9). NMR titration experiments revealed that these three residues
are essential for the interaction since their substitution abolished
the complex formation with Fyn SH3 (Fig. 1B).
Multiple prolines are favorable to the interaction with SH3
domains since the pyrrolidone rings conformationally restrict the
polypeptide and promote the formation of a sterically driven left
handed PPII helix. In particular additional prolines are commonly
found in P2 and P5 positions as it is the case for the CtErbB2
[RPQPPSP]-site. The presence of additional proline residues facili-
tates SH3 binding by stabilizing the PPII conformation and induc-
ing the optimized spacing and orientation of the key residues for
the interaction. We thus investigated the binding of a mutant of
the R1P2Q3P4P5S6P7R8E9 peptide where P2, P5 and R8 were substi-
tuted by alanine (R1A2Q3P4A5S6P7A8E9). NMR titration performed
with this mutant indicated that residues P2, P5 and R8 were not
essential for the interaction of the peptide with Fyn-SH3
(Fig. 1C). Moreover, the 3JHNa coupling constants found in this
mutant were in agreement with a conserved PPII helix in the
R1A2Q3P4A5S6P7A8E9 peptide.CtErbB2 [RPQPPSP]-site: RPQPPS PRE
Peptide 91-104 of the p85 subunit :   PPRPL PVAPGSSLT
A
B
C
Fig. 4. (A) 25 lowest energy structures of ErbB2 R1P2Q3P4P5S6P7R8E9 peptide, (B) 25
lowest energy structures of the peptide 91–104 of p85 from the complex with Fyn
SH3 domain (PDB code: 1A0N), (C) Sequences of CtErbB2 [RPQPPSP]-site peptide
and peptide 91–104 of p85 subunit of PI3-Kinase.
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Fig. 5. (A) Weighted average chemical shift variations (Dd) observed on resonances of Fyn SH3 domain in the presence of R1P2Q3P4P5S6P7R8E9 peptide,
Dd ¼ ðDdH2 þ ðDdN2 =25Þ1=2Þ [26], (B) chemical shift mapping of R1P2Q3P4P5S6P7R8E9 peptide interacting site on Fyn SH3 domain within the structure of p85 peptide/Fyn
SH3 complex (PDB code: 1A0N). Fyn SH3 residues are in grey, Fyn SH3 residues affected by the presence of R1P2Q3P4P5S6P7R8E9 peptide are in green and peptides 91–104 of
p85 subunit of PI3-Kinase residues are in red.
Fig. 6. Src kinase SH3 domain sequence alignment. C-Src, Fyn, c-Yes, Fgr, Blk, Hck, Lck and Lyn sequences of SH3 domains are represented. In red are the Fyn SH3 residues
affected by human CtErbB2 R1P2Q3P4P5S6P7R8E9 peptide.
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15N HSQC recorded on free and bound Fyn SH3 domain indi-
cated a speciﬁc chemical shift variation induced by the R1P2Q3P4P5-
S6P7R8E9 peptide. We obtained sequential NH assignments of the
free and R1P2Q3P4P5S6P7R8E9 peptide bound Fyn SH3 domain using
heteronuclear experiments. On the basis of chemical shift varia-
tions, we could map the interacting surface (Fig. 5A). The interact-
ing interface is very similar to that observed in the structure of p85
peptide 91–104/Fyn SH3 complex (PDB code: 1A0N) (Fig. 5B). The
residues affected by the complex formation are respectively
located in the RT-loop, the n-Src loop, the distal loop and the ring
of the W119, as it was previously reported for numerous Fyn SH3/
polyproline motif complexes [12].An intriguing question is why are proline-rich motifs widely
distributed in eukaryote cells? [13]. PPII helices are stable and
resistant structures, that are relatively permissive to amino acid
substitutions. Therefore various combinations of non-proline and
proline residues do not compromise these structural frames. The
non-proline residues located in positions 1, 3 and 6 are at the con-
tacting interfaces and among ligands of Src kinase SH3 domains,
except R1, the other residues are variable playing an important role
in the ligand speciﬁcity (Fig. 4C).
SH3 domains constitute one of the best-known protein-interac-
tion modules [14]. These domains play critical roles in a great
number of biological processes, binding Pro-rich motifs with low
afﬁnity [15]. SH3 domains from the Src kinase family are interest-
ing examples of the balance between promiscuity and speciﬁcity.
2036 O. Bornet et al. / FEBS Letters 588 (2014) 2031–2036Src kinase family contains nine members c-Src, c-Yes, Fyn, Lyn, Lck,
Hck, Blk, Fgr and Yrk which share a SH3 domain responsible for the
recruitment of polyproline motifs. A sequential alignment of SH3
domains of SFKs is provided in Fig. 6. One can observe that the res-
idues in Fyn-SH3 domain affected by the presence of the R1P2Q3P4-
P5S6P7R8E9 peptide are highly conserved among the SFKs. This data
is in agreement with the redundant functions of SFKs in the cell.
However, there is an increasing number of evidence for SFK spec-
iﬁcity in signaling.
3.4. Src family kinases in ErbB2 positive breast cancer
SFKs association with ErbB2 has been shown in human breast
cancer cell lines and tumors [16–18]. For instance, high Src activity
correlates with ErbB2 positivity and high tumor grade in ductal
carcinoma in situ [19]. This interaction results in enhanced Src
activity and stability [20,21]. The recent observations that various
SFKs, including c-Src, c-Yes, Fyn and Lck, contribute to resistance to
ErbB2-targeting drugs [22,23] further support the importance of
delineating SFK contribution to ErbB2 signaling. Src physically
associates with ErbB2, but the mechanism is still unclear, as stud-
ies involved either the SH2 or the catalytic domain [16,24,25].
Herein, we have identiﬁed a PPII motif in human ErbB2 C-terminus
that interacts with Fyn-SH3 domain and thus could contribute to
SFKs interaction with ErbB2. In the future, it will be important to
determine, beyond Fyn, which SFK SH3 domains actually interact
with ErbB2, and if additional SFK domains or other motifs in
CtErbB2 contribute to deﬁne SFK afﬁnity and speciﬁcity for the
ErbB2 receptor tyrosine kinase.
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